DataHow Boosts Bioprocess AI with New Funding

DataHow AG, a Swiss innovator in AI-driven biopharmaceutical development, has successfully closed an extension to its Series A funding round. This crucial capital infusion, led by existing investor Momenta, with continued support from Rockwell Automation, HINA Bioventures, and Zürcher Kantonalbank, will fuel the company's strategic push into real-time process monitoring and downstream manufacturing applications.

The fresh capital injection is earmarked for three key areas that will significantly enhance the capabilities of DataHow's flagship digital bioprocess development and manufacturing platform, DataHowLab. These priorities include establishing direct real-time connectivity to laboratory and production systems, implementing advanced model-driven process control, and extending the platform's reach into downstream processing (DSP) operations. This move aims to provide a comprehensive, end-to-end digital solution for bioprocess engineers.

Since its initial Series A financing, DataHow has demonstrated considerable traction, deploying its proprietary hybrid modeling technology with major biopharmaceutical manufacturers. This technology uniquely blends established process knowledge with adaptive AI, offering enhanced insights and decision support while simultaneously reducing experimental timelines and costs. The sustained confidence and renewed investment from its existing partners underscore the company's robust progress and the significant market opportunity ahead.

The expansion into real-time connectivity, a direct result of ongoing collaborations with clients and partners like Rockwell Automation, will enable DataHowLab to integrate seamlessly with existing operational infrastructure. This forms the foundation for enabling human-in-the-loop process guidance and, eventually, fully autonomous disturbance rejection and optimization. The strategic extension into downstream processing will complement DataHowLab's existing strengths in upstream processing (USP), creating a unified intelligence platform for the entire biomanufacturing lifecycle. This holistic approach is becoming increasingly vital in the biopharma sector, where efficiency and consistency are paramount.

Dr. Alessandro Butté, CEO and co-founder of DataHow, expressed gratitude for the investors' continued belief, stating, "Our customers are consistently urging us to advance our technologies further and earlier in the process, particularly into real-time environments and downstream operations. This funding empowers us to directly address this demand and evolve the platform to meet their immediate needs." This sentiment is echoed by Ken Forster of Momenta, who noted, "DataHow's progress toward real-time, model-driven process control represents the critical shift from automation to autonomy that will define the future of industrial manufacturing."

The biopharmaceutical industry is undergoing a profound digital transformation, with a growing emphasis on data-driven decision-making and intelligent automation. Companies like DataHow are at the forefront of this shift, enabling a move from retrospective analysis to predictive, model-driven control. This enhances agility, ensures greater consistency, and boosts overall operational performance. As AI becomes a cornerstone of modern manufacturing, DataHow's integrated platform is well-positioned to accelerate the industry's transition toward more autonomous production environments, a critical factor in keeping pace with the accelerating drug discovery and development cycles.